Suven Pharmaceuticals Renamed as Cohance Lifesciences
ECONOMY & POLICY

Suven Pharmaceuticals Renamed as Cohance Lifesciences

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences.

This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics.

The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide.

"The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world" said Cohance Executive Chairman, Vivek Sharma.

The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals” to “Cohance Lifesciences”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation.

The Company would make necessary application to the BSE and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences.”

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences. This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics. The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide. The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world said Cohance Executive Chairman, Vivek Sharma. The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals” to “Cohance Lifesciences”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation. The Company would make necessary application to the BSE and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences.”

Next Story
Infrastructure Urban

DCPC Prepares for Special Campaign 5.0 with Focus on E-Waste

The Department of Chemicals and Petrochemicals (DCPC), Ministry of Chemicals and Fertilisers, is gearing up for Special Campaign 5.0, to be held from 2nd to 31st October 2025. The initiative will focus on e-waste disposal as per MoEFCC’s E-Waste Management Rules 2022, space optimisation, and enhancing workplace efficiency across field offices.Special Campaign 4.0, conducted between October 2023 and October 2024, delivered notable results in record management, grievance redressal, scrap disposal, and cleanliness drives.Key outcomes of Special Campaign 4.0Records management: 2,443 physical fil..

Next Story
Real Estate

BlackRock India Leases 1.4 Lakh Sq Ft in Bengaluru

BlackRock Services India, the domestic arm of global asset manager BlackRock, has leased 1.4 lakh sq ft of office space at IndiQube Symphony in Bengaluru, according to Propstack data. The 10-year deal is valued at around Rs 4.10 billion.The lease, among the largest transactions in India’s co-working sector, highlights the growing preference of global institutions for flexible office providers. The agreement, commencing October 1, 2025, covers ground plus five floors in KNG Tower 1 at Ashoknagar, MG Road — one of Bengaluru’s prime commercial hubs.As per the lease document, BlackRock will ..

Next Story
Infrastructure Transport

L&T Bags Rs 25–50 Bn Order for Mumbai-Ahmedabad Bullet Train Track Works

Larsen & Toubro’s (L&T) Transportation Infrastructure business has secured an order valued between Rs 25 crore and Rs 50 billion from the National High Speed Rail Corporation Limited (NHSRCL) for the Mumbai-Ahmedabad High Speed Rail (MAHSR) corridor.The contract, Package T1, involves the design, supply, construction, testing, and commissioning of 156 route km of high-speed ballastless track on a Design-Build Lump Sum Price basis. The stretch runs from Mumbai’s Bandra-Kurla Complex to Zaroli village in Gujarat and includes 21 km of underground track and 135 km of elevated viaduct.Se..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?